Small Business: Biologic-based Therapeutic Development for Alzheimer’s Disease, Related Dementias and Neurodegenerative Disorders – NPB (11)
This review panel reviews applications dealing with basic and clinical aspects of drug discovery in treatment of aging and neurodegenerative disorders, including mild-cognitive impairment, Alzheimer’s disease and related dementias, movement degenerative disorders such as Parkinson’s, Huntington’s, amyotrophic lateral sclerosis. The scope of therapeutic formats covered includes biologics such as molecular manipulation and engineering, monoclonal antibodies, vaccines, gene and stem cell therapies, and proteins/neuropeptides that interact with and modulate neuroreceptors, transporters and transducers.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Interventions for senescence of nerve cells, cognitive aging, and mild cognitive impairment (MCI)
- Alzheimer’s disease (AD)
- Alzheimer’s related dementia (ADRD) including frontotemporal dementia (FTD), Lewy body dementia (LBD), Limbic-predominant age-related TDP-43 encephalopathy (LATE), and Creutzfeldt-Jakob disease (CJD)
- Neurodegenerative movement disorders such as Parkinson’s diseases (PD), essential tremor, ataxia, Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), etc.
- Approaches utilized include biologics, cell and gene based therapies, as well as protein and neuropeptides. The range of studies include pre-clinical as well as roof of principle early stage clinical studies.
